Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Don't Let The Market Fool You: Bristol-Myers Is Not A Value Trap

Stock market investing is not a zero-sum game, offering long-term potential for growth and income when it comes to highly undervalued stocks. Bristol Myers Squibb stock is undervalued, with strong revenue growth, profitability, and a promising drug pipeline. BMY presents a high conviction buy opportunity for value and income investors, with potential for future growth and acquisitions.

Bristol Myers Squibb: The More It Drops, The More I Buy

British American Tobacco

Boston Properties

Enbridge

TotalEnergies SE

Verizon

24/7 Insights Traders are betting that the first federal funds rate cut will come in September.

The Rate Cut Is On: Buy These 6 High-Yield Dividend Stocks Now

Bristol-Myers Squibb investors have been unable to avoid further battering over the past few months. BMY's downgraded full-year outlook didn't help, as investors reassessed higher execution risks. BMY must justify its optimism in turning around its LOEs with its recent acquisitions.

Bristol-Myers Squibb: Seriously Undervalued And Poised For An Inflection

Amazon

Healthcare and tech are booming, and these businesses are great ways to play each industry. Bristol Myers Squibb is going through a transition period, but the dividend payer has a lot to offer investors.

Got $500? 2 No-Brainer Growth Stocks to Buy and Hold Forever

Cisco Systems

Starbucks

Bristol Myers faces multiple challenges, but if it can overcome them, its stock could prove to be a steal of a deal. Cisco's sales haven't gotten a boost yet from AI, but it may only be a matter of time before that changes.

3 High-Yielding Dividend Stocks Near Their 52-Week Lows

Pfizer

Pfizer and Bristol Myers have faced issues recently that have led to poor stock market performances. However, both drugmakers are spinning their innovative wheels and look likely to bounce back.

2 Pharma Stocks to Buy Hand Over Fist This Month

Bristol Myers (BMY) faces an uphill struggle as top drugs face challenges. We advise investors to steer clear for the time being.

Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?

Comerica

Altria

24/7 Insights Dividend stocks offer investors the opportunity to increase investment total return.

5 Under $50 Dividend Stocks to Buy Now

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $40.75, denoting a -0.9% change from the preceding trading day.

Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights

Blackstone Secured Lending Fund

Realty Income Corp

Neos S&P 500 High Income ETF

Markets started the 2nd half of 2024 strong, with S&P up 1.69% and Nasdaq up 3.29%. Earnings season approaching, with the banking sector first, followed by the Magnificent Seven. Dividend Harvesting Portfolio hits all-time high, generating $44.41 in dividend income in the first week of July.

Dividend Harvesting Portfolio Week 175: $17,500 Allocated, $1,566.24 In Projected Dividends

Medtronic

Magna International

As the second half of 2024 unfolds, main Wall Street indices are reaching new highs. The Nasdaq 100 index soared more than 20% year-to-date, and the S&P 500 saw an all-time high with a 16% surge.

3 Undervalued Stocks Ready for a Breakout This Summer

Ares Capital

PennantPark Floating Rate Capital

Bristol Myers Squibb's earnings outlook revision was disturbing but hardly a reason to avoid the Big Pharma stock. With a yield above 10%, PennantPark Floating Rate Capital is hard for income-seeking investors to ignore.

Want $1,000 in Reliable Dividend Income? Invest $11,800 in these 3 Ultra-High-Yield Dividend Stocks.

Apple

AbbVie

Chevron

Kroger

Occidental Petroleum

Visa

I just read an article that quoted billionaire hedge fund manager, David Einhorn, as saying value investing was dead. Since I'm writing about the best Warren Buffett stocks, that thought piqued my interest.

The 7 Best Warren Buffett Stocks to Buy in July 2024

AT&T

Vici Properties

Bristol Myers Squibb upset investors with a big acquisition-related expense, but its pharmaceutical business is stronger than ever. Vici Properties is a real estate investment trust that collects rent from some of the largest casino operators in Las Vegas.

3 High-Yield S&P 500 Dividend Stocks That You Can Buy With $100 Right Now

Comcast

Dividend stocks for your July 2024 watchlist.

Top Dividend Stocks To Buy In July 2024? 2 In Focus

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day.

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Clearway Energy

Universal Corp

Despite markets reaching new heights recently, many defensive stocks with reliable and consistent demand are still experiencing their own market dip. They have pulled back as investors repositioned into the artificial intelligence (AI) trend.

3 Defensive Stocks to Buy During the Market Dip

Pfizer's been raising its dividend payout for 15 years, and a heap of new products could help it continue the streak. The largest publicly traded business development company, Ares Capital offers investors a yield above 9% at recent prices.

3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With $100 in July

Walgreens

24/7 Insights Wounded blue chip stocks can offer huge total return potential.

Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now

Campbell Soup

Dow Inc

Duke Energy

Gilead Sciences

Johnson & Johnson

Kinder Morgan

Polaris

PNC Financial Services

SPDR S&P 500 ETF Trust

Sempra Energy

Toronto-Dominion Bank

U.S. Bancorp

Morningstar published 10 Best Value Stocks to Buy for the Long Term, undervalued blue-chip stocks with low price to fair value. Valuation and future return of each stock analyzed, compared to the S&P 500, Bristol-Myers has the highest potential rate of return. In comparison to Morningstar's 10 Best Value Stocks with 10 Best Dividend Stocks, Bristol-Myers stands out as undervalued with a high potential return.

Going Beyond Morningstar's 10 Best Value Stocks List

Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition Authority said on Monday.

Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges

W. P. Carey

AI stocks like Nvidia, Super Micro Computer, and Dell Technologies are leading the market but may be in bubble territory. Value stocks like W.P. Carey and Bristol Myers Squibb offer beaten-down prices, high dividend yields, and potential for market-beating returns. W.P. Carey yields 6.3% and offers growth potential through European property acquisitions, while Bristol Myers Squibb gives a 5.6% yield and has growth prospects driven by a strong drug pipeline.

Buy The Drop On These 6% Dividend Value Picks

BMY stock has seen a rapid correction, but my analysis suggests it's a buy the dip opportunity. Read on. Despite challenges with patent expirations, BMY's product line and pipeline development show promise for future growth. With an implied P/E multiple of 6.1x for FY2025, BMY appears undervalued, offering a potential 64% upside by the end of 2025.

Bristol-Myers Squibb: Time To Double Down

Vanguard Total Bond Market ETF

Disney

Fidelity National Information

Fragile stagflation presents challenges for investors, with limited opportunities for good returns in stocks and bonds. It is likely markets will experience a lost decade in real terms when measured from 2022. I share 5 stocks I recently sold, why I sold them, my barbell strategy, and how much cash I am holding in my investment portfolios.

News for Bristol-Myers Stock (BMY)